Physician profile
Robert H Bevis
NPI 1003887621
$6,493.48
in general payments reported to CMS, 2019-2025
30 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.56 · 2020: $39.01 · 2021: $1,076 · 2022: $1,643 · 2023: $1,108 · 2024: $1,114 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.72 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,097.10 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,021.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $889.12 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.89 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $456.40 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $362.61 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $317.51 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $288.68 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Esperion Therapeutics, INC. | $198.37 | 2021-2025 | Nexletol |
| Dexcom, INC. | $160.98 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $149.62 | 2021-2025 | Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.89 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $111.25 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $98.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $96.73 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $66.65 | 2019-2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $65.13 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $61.28 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $53.64 | 2024 | Heplisav-B |
| Biocomposites INC | $51.97 | 2025 | Stimulan |
| Janssen Pharmaceuticals, INC | $49.22 | 2021-2022 | |
| Vivus LLC | $36.67 | 2021-2022 | |
| Astellas Pharma US INC | $36.46 | 2022-2023 | Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $28.40 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $21.94 | 2023 | Voquezna |
| Amarin Pharma, INC. | $18.51 | 2022 | |
| Daiichi Sankyo INC. | $18.12 | 2023 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $15.75 | 2021 | |
| Lundbeck LLC | $13.92 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bevis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.